临床难题:溶栓在视网膜中央动脉阻塞中的作用是什么?
本文讨论一例71岁女性在2.5小时内因急性CRAO就诊的病例,评估静脉溶栓是否适用。早期观察性研究和患者水平荟萃分析曾支持溶栓,但更新的两项随机对照试验(THEIA和TenCRAOS)显示,与阿司匹林相比,阿替普酶或替奈普酶均未改善视力恢复,且溶栓组有更多不良事件趋势或症状性颅内出血。因此,急诊医生应优先进行快速诊断、眼科和神经科会诊、卒中评估及二级卒中预防,而非常规溶栓。
要点
- 现有证据不支持对急性非动脉炎性CRAO患者常规使用静脉溶栓;应优先快速诊断、眼科与神经科会诊、卒中评估及二级卒中预防。
- THEIA试验发现,与阿司匹林相比,4.5小时内静脉阿替普酶未改善严重视力丧失CRAO患者的视力恢复,且不良事件有增多趋势(Preterre 2025)。
- TenCRAOS试验显示,替奈普酶与阿司匹林在视力恢复上无显著差异,且溶栓组报告1例症状性颅内出血(Ryan 2026)。
- 2021年AHA科学声明曾建议在4.5小时内经仔细筛选的患者中考虑溶栓,但当时缺乏随机证据(Mac Grory 2021)。
- CRAO视网膜侧支循环极少,可导致快速不可逆缺血损伤;视网膜血管管径小且病因异质,可能降低全身溶栓的有效性(Hayreh 2011)。
适用人群与场景
- 急诊场景中的急性CRAO患者,例如突然单眼视力丧失的患者。
- 原文病例:71岁女性,有高血压和心房颤动史,突发左眼视力丧失2.5小时。
- 原文提及的急性非动脉炎性CRAO患者。
诊断标准与关键阈值
- 诊断标准为急性CRAO:床边POCUS显示球后「点征」,同时CTA阴性,结合突发单眼视力丧失。
- 原文未提及具体的视力评分界值或溶栓启动/停止阈值。
处置流程与药物剂量
- 第一步:快速诊断,例如使用床边POCUS确认球后「点征」并排除其他病因(原文病例中CTA阴性)。
- 第二步:请眼科和神经科会诊,并启动卒中评估及二级卒中预防。
- 原文未提及具体药物剂量、给药途径、频次或疗程;不常规使用静脉溶栓。
红旗征与不能漏的情况
- 溶栓组可能存在不良事件增多趋势(THEIA试验,Preterre 2025),以及症状性颅内出血风险(TenCRAOS试验报告1例,Ryan 2026)。
- CRAO仍属于血管急症,需快速识别和处理,但溶栓治疗未被证明能改善视力结局。
研究设计与关键结果
- THEIA试验:比较静脉阿替普酶与口服阿司匹林治疗4.5小时内严重视力丧失的CRAO,发现阿替普酶未改善视力恢复,且不良事件有增多趋势(Preterre 2025)。
- TenCRAOS试验:比较替奈普酶与阿司匹林,视力恢复无显著差异,溶栓组报告1例症状性颅内出血(Ryan 2026)。
- 早期支持溶栓的证据主要来自观察性研究和患者水平荟萃分析,例如Schrag 2015。
- 2021年AHA科学声明建议在4.5小时内经仔细筛选的患者中考虑溶栓,但当时缺乏随机证据(Mac Grory 2021)。
- 视网膜侧支循环极少,可导致快速不可逆缺血损伤;视网膜血管管径小且病因异质,可能降低全身溶栓有效性(Hayreh 2011)。
证据类型、等级与局限
- 证据类型:更新的两项高质量随机对照试验(THEIA和TenCRAOS)提供目前最强证据,优于早期观察性研究和患者水平荟萃分析。
- 早期证据主要来自观察性研究和患者水平荟萃分析(Schrag 2015;Dumitrascu 2020)。
- 随机对照试验减少了非随机设计固有的选择偏倚和混杂,因此证据强度更高。
- 原文未给出指南的推荐等级或证据分级体系。
对床旁实践的改变
- 不改变常规溶栓决策:急诊和ICU医生不应将静脉溶栓作为急性CRAO的常规治疗。
- 改变实践重点:应优先进行快速诊断、眼科和神经科会诊、卒中评估及二级卒中预防。
- 不适用人群:原文未提及可常规使用静脉溶栓的亚组;即使传统4.5小时时间窗内也不建议常规溶栓。
- 常见陷阱:将CRAO类比为脑卒中而推断溶栓有效,忽略了视网膜侧支循环极少、血管管径小及病因异质性等差异。
指南或共识出处
- 2021年AHA科学声明:Management of central retinal artery occlusion(Mac Grory 2021)。
原文图文 · 图 17 张


REBEL Rundown

Bottom Line Up Top
Current evidence does not support the routine use of intravenous thrombolysis for acute central retinal artery occlusion (CRAO).

Case
A 71 year old woman with hypertension and atrial fibrillation presents 2.5 hours after the sudden onset of vision loss in her left eye. Examination demonstrates profound monocular vision loss, CTA is negative but bedside POCUS shows a retrobulbar spot sign, confirming the diagnosis of acute CRAO. Because she presents within the traditional 4.5 hour thrombolytic window, you consider whether intravenous thrombolysis should be administered.

What Your Gut Says
CRAO is commonly referred to as an “eye stroke.” If thrombolytics improve outcomes in acute ischemic stroke, they should similarly be helpful in restoring vision in CRAO.

What The Evidence Says
CRAO is an acute ischemic injury of the retina, most commonly caused by an embolic occlusion of the central retinal artery or one of its branches. Because the retinal and cerebral circulations share a common vascular origin, thrombolysis has long been considered a potential treatment strategy (Dumitrascu 2020; Mac Grory 2021). Important anatomical differences distinguish CRAO from cerebral stroke. The retina has minimal collateral circulation, resulting in rapid, irreversible ischemic injury. In addition, the small caliber of the retinal vasculature and the heterogeneous causes of CRAO may reduce the effectiveness of systemic thrombolysis (Hayreh 2011).
Early evidence supporting thrombolysis came primarily from observational studies and patient level meta analyses. This led to the 2021 American Heart Association Scientific Statement to recommend considering thrombolysis in carefully selected patients presenting within 4.5 hours while acknowledging the absence of randomized evidence (Mac Grory 2021; Schrag 2015).
More recently, two high quality randomized controlled trials have challenged this practice. In contrast to the earlier observational studies and patient level meta analyses, these trials reduce important sources of bias inherent to non-randomized designs including selection bias and confounding, and therefore provide the strongest evidence available to date. The THEIA trial found no improvement in visual recovery with intravenous alteplase compared with aspirin and demonstrated a trend toward more adverse events (Preterre 2025). Likewise, the TenCRAOS trial showed no significant difference in vision recovery between tenecteplase and aspirin while reporting one symptomatic intracranial hemorrhage in the thrombolysis group (Ryan 2026). Together, these studies suggest that the potential risks of thrombolysis outweigh any unproven benefit.

Clinical Bottom Line
Routine intravenous thrombolysis is not supported for patients with acute nonarteritic CRAO. Emergency physicians should instead prioritize rapid diagnosis, ophthalmology and neurology consultation, stroke evaluation, and secondary stroke prevention. Although CRAO remains a vascular emergency, current evidence suggests that thrombolytic therapy does not improve visual outcomes and may expose patients to unnecessary harm (Preterre 2025; Ryan 2026).

References
Dumitrascu, O. M., Newman, N. J., & Biousse, V. (2020). Thrombolysis for central retinal artery occlusion in 2020: Time is vision! Journal of Neuro-Ophthalmology, 40(3), 333–345. PMID: 32739995
Hayreh, S. S. (2011). Ocular vascular occlusive disorders: Natural history of visual outcome. Progress in Retinal and Eye Research, 30(5), 359–394. PMID: 24769221
Mac Grory, B., et al. (2021). Management of central retinal artery occlusion: A scientific statement from the American Heart Association. Stroke. PMID: 33677974
Preterre, C., Gaultier, A., Obadia, M., et al. (2025). Intravenous alteplase versus oral aspirin for acute central retinal artery occlusion within 4.5 hours of severe vision loss (THEIA): The Lancet Neurology. PMID: 41109232
Ryan, S. J., Jørstad, Ø. K., Skjelland, M., et al. (2026). A randomized trial of tenecteplase in acute central retinal artery occlusion. New England Journal of Medicine, 394(5), 442–450. PMID: 41604638
Schrag, M., Youn, T., Schindler, J., Kirshner, H., & Greer, D. (2015). Intravenous fibrinolytic therapy in central retinal artery occlusion: A patient level meta analysis. JAMA Neurology, 72(10), 1148–1154. PMID: 26258861
Post Peer Reviewed By: Mark Ramzy, DO (X: @MRamzyDO), and Marco Propersi, DO (X: @Marco_Propersi)
Authors

Jalyn DiBello MD
Medical Education Fellow
Staten Island University Hospital

Anand Swaminathan, MD, MPH
Associate Professor Emergency Medicine, Zucker School of Medicine
Staten Island University Hospital
Showing Slide 1 of 2

Your Deep-Dive Starts Here

Clinical Conundrum: Is Acetaminophen Safe in Pregnancy?
In the first trimester, fever is associated with increased risk ...
Obstetrics and Gynecology
Read More

Clinical Conundrum: Is Tamsulosin Effective in Increasing Spontaneous Passage Rate of Ureteral Stones?
Procalcitonin is a protein that is upregulated during inflammatory states. ...
Renal and Genitourinary
Read More

Seizing the Evidence: Should We Consider Ketamine’s Place in Seizure Protocols?
Ketamine was first introduced for human use in 1965 and ...
Neurology
Read More

Clinical Conundrum: Pregnant and Puking: What’s Safe and Effective in the ED?
Nausea with or without vomiting is very common in early ...
Obstetrics and Gynecology
Read More

Clinical Conundrum: What is the Utility of Procalcitonin in the ED?
Procalcitonin is a protein that is upregulated during inflammatory states. ...
Infectious Disease
Read More

Clinical Conundrum: Does IM Ketorolac Provide Superior Pain Relief to PO Ibuprofen?
Clinical Scenario: A 34-year-old woman presents to the ED with ...
Trauma
Read More
Showing Slide 1 of 6: Clinical Conundrum: Is Acetaminophen Safe in Pregnancy?
The post Clinical Conundrum — What is the Role of Thrombolysis in Central Retinal Artery Occlusion? appeared first on REBEL EM - Emergency Medicine Blog.
参考来源
- REBEL EM:Clinical Conundrum — What is the Role of Thrombolysis in Central Retinal Artery Occlusion?
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。